176721-02-1

Basic information

• Product Name: (2,3-Dimethylphenyl)[1-(trityl)-1H-imidazol-4-yl]methanone
• Synonyms: (2,3-Dimethylphenyl)[1-(trityl)-1H-imidazol-4-yl]methanone;(2,3-Dimethylphenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]methanone;(2,3-Dimethylphenyl)(1-trityl-1H-imidazol-5-yl)methanone;(2,3-Dimethylphenyl)-(3-trityl-3H-imidazol-4-yl)methanone;1-(2,3-dimethylphenyl)-1-(1H-imidazol-4-triphenylmethyl)methanone
• CAS NO: 176721-02-1
• Molecular Formula: C₃₁H₂₆N₂O
• Molecular Weight: 442.55094
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 176721-02-1.mol

Chemical Properties

• Appearance: /
• Density: 1.09
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: (2,3-Dimethylphenyl)[1-(trityl)-1H-imidazol-4-yl]methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (2,3-Dimethylphenyl)[1-(trityl)-1H-imidazol-4-yl]methanone(176721-02-1)
• EPA Substance Registry System: (2,3-Dimethylphenyl)[1-(trityl)-1H-imidazol-4-yl]methanone(176721-02-1)

Safety Data

• Hazardous Substances Data: 176721-02-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2,3-Dimethylphenyl)[1-(trityl)-1H-imidazol-4-yl]methanone is used as a synthetic intermediate for the preparation of dexmedetomidine from medetomidine intermediate. (2,3-Dimethylphenyl)[1-(trityl)-1H-imidazol-4-yl]methanone plays a crucial role in the development of dexmedetomidine, which is utilized for its sedative, analgesic, and anxiolytic properties in various medical procedures, including intensive care, anesthesia, and veterinary medicine.
Chemical Properties:
The compound is a white solid, which indicates its stable and non-volatile nature. This property is essential for its use in the synthesis of dexmedetomidine, as it allows for easier handling and processing during the chemical reactions involved in the production process.

Upstream product

• 576-23-8 2,3-dimethylbromobenzene 
• 76074-88-9 methyl 1-(triphenylmethyl)-1H-imidazole-4-carboxylate 
• 53525-60-3 4-carbethoxy-1-triphenyl methyl-1H-imidazole 
• 76-83-5 trityl chloride 
• 33016-47-6 (1-tritylimidazol-4-yl)carboxaldehyde 
• 176721-01-0 4-<(2,3-dimethylphenyl)hydroxymethyl>-1-(triphenylmethyl)imidazole 

Downstream Products

• 176721-03-2 4-<1-(2,3-dimethylphenyl)-1-hydroxyethyl>-1-(triphenylmethyl)imidazole 
• 176721-04-3 (S)-dexmedetomidine-L-(+)-tartrate 
• 86347-14-0 (+/-)-4(5)-<1-(2,3-Dimethylphenyl)ethyl-1H-imidazole> 
• 1021949-47-2 1-(4-imidazolyl)-1-(2,3-dimethylphenyl)ethylene 
• 113775-47-6 dexmedetomidine 
• 86347-14-0 medetomidine 

Relevant articles and documents

A right-US supporting [...] and its hydrochloride preparation method

Invention provides a right-US supporting [...] and its hydrochloride preparation method. In particular, the invention using carbon-carbon hydrogenation reduction catalyst and (R, S) - Duanphos composition as a catalyst to the double bond of a chiral catalytic reduction, directly by the enantiomeric excess percentage up to 99.9% of the right us holds the onamot to decide, the preparation method of the present invention short synthetic route, the product does not need to chiral separation, high yield.

Preparation method of dexmedetomidine hydrochloride and its intermediate

The invention discloses a preparation method of dexmedetomidine hydrochloride and its intermediate. A preparation method of dexmedetomidine L-tartrate comprises the steps of subjecting dexmedetomidineintermediate III and hydrogen to reduction reaction in an organic solvent in the presence of a chiral catalyst, and subjecting the reduced product and tartaric acid to neutralization reaction to obtain dexmedetomidine L-tartrate II, wherein the chiral catalyst is (+)-1,2-bis(2S-5S)-diethylphospholano-benzene(1,5-cyclooctadiene)rhodium trifluoromethanesulfonate. The preparation method herein has ashort step path, has no need for chiral splitting, and has high total molar yield; the product prepared herein has high purity, reaches the standard for bulk pharmaceutical chemicals and is suitablefor industrial production.

Intermediate for preparing medetomidine and its preparation method and use

The invention provides an intermediate for preparing medetomidine. The intermediate is a compound shown in the formula (I). The invention also provides a preparation method of the intermediate, and ause of the intermediate in the preparation of medetomidine. The compound shown in the formula (I) is used for preparation of medetomidine so that the raw material is cheap and easy to obtain, synthesis processes are simple, the reaction cycle is short, the environmental pollution is avoided, operation is simple, the harsh reaction conditions are avoided, the operation and post-treatment are simple, the yield and the product purity are high, the intermediate in each step is a solid and is easy to purify, a production cost is low, and the intermediate is suitable for industrial large-scale production and conforms to the principle of green chemistry.

A novel and facile route for the synthesis of medetomidine as the α2-adrenoceptor agonist

Abstract: We report here a novel and facile method for the synthesis of (±)-4(5)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole (medetomidine) in a good yield in five steps. The method involves Wittig olefination of the phenylimidazolylketones, followed by a hydrogenation. We demonstrate that the Wittig alkenylation reaction provides a convenient step for the synthesis of medetomidine without requiring methylation and dehydration steps, which are problematic processes in the previous methods. Graphical Abstract: Novel route for the synthesis of medetomidine.[Figure not available: see fulltext.].

PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE

The present invention discloses a preparation method of 2,3-dimethyl phenyl-1-trityl-imidazole-4-ketone. In accordance with this method, imidazole-4-ethyl formate is used as a raw material; ethyl formate is used for amino protection, 1-trityl-1H-imidazole

Method for preparing medetomidine and its salts

The invention provides an improved, highly efficient method for preparing Medetomidine, and its salts, in particular its pharmaceutically acceptable salts. The method utilizes the high reactivity of halogenated imidazoles towards transmetalation with Grignard reagents and the subsequent reaction with 2,3-dimethylbenzaldehyde.

Efficient synthesis of (S)-4(5)-[1-(2,3-dimethylphenyl) ethyl]imidazole tartrate, the potent α2 adrenoceptor agonist dexmedetomidine

(S,R)-4(5)-[1-(2,3-dimethylphenyl)ethyl]imidazole 5 is prepared in 41% yield, by a new reliable method from readily available starting materials. The separation of the enantiomers proceeds through the selective crystallisation of the (+)-tartrate of the (S) enantiomer 6 in the presence of the (R) enantiomer free base.